• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial].

作者信息

Wouters E F M, Postma D S, Fokkens B, Hop W C, Prins J, Kuipers A F, Pasma H R, Hensing C A J, Creutzberg E C

出版信息

Rev Port Pneumol. 2005 Nov-Dec;11(6):587-9.

PMID:16514718
Abstract
摘要

相似文献

1
[Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial].
Rev Port Pneumol. 2005 Nov-Dec;11(6):587-9.
2
Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.慢性阻塞性肺疾病（COPD）患者从沙美特罗/丙酸氟替卡松联合治疗中撤用丙酸氟替卡松会导致疾病立即且持续恶化：一项随机对照试验
Thorax. 2005 Jun;60(6):480-7. doi: 10.1136/thx.2004.034280.
3
Fluticasone/salmeterol: labeling change.氟替卡松/沙美特罗：标签变更。
Prescrire Int. 2008 Dec;17(98):229.
4
Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.在哮喘或慢性阻塞性肺疾病（COPD）的家庭医疗患者中，使用氟替卡松/沙美特罗联合制剂可降低吸入性类固醇的需求量。
Fam Pract. 2007 Apr;24(2):181-8. doi: 10.1093/fampra/cml076. Epub 2007 Jan 23.
5
Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.丙酸氟替卡松/沙美特罗（250/50微克）或沙美特罗（50微克）对慢性阻塞性肺疾病急性加重的影响。
Respir Med. 2008 Aug;102(8):1099-108. doi: 10.1016/j.rmed.2008.04.019. Epub 2008 Jul 9.
6
Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.预测严重 COPD 患者对丙酸氟替卡松/沙美特罗联合治疗反应的因素。
Respir Med. 2011 Feb;105(2):250-8. doi: 10.1016/j.rmed.2010.07.009. Epub 2010 Aug 10.
7
[Salmeterol + fluticasone in COPD. Complementary treatment principles hold true in the COPD management, too].
MMW Fortschr Med. 2003 Nov 13;145(46):47.
8
The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study.吸入用丙酸氟替卡松/沙美特罗与异丙托溴铵/沙丁胺醇治疗慢性阻塞性肺疾病的疗效和安全性：一项为期8周的多中心、随机、双盲、双模拟、平行组研究。
Clin Ther. 2005 May;27(5):531-42. doi: 10.1016/j.clinthera.2005.05.009.
9
COPD: don't use fluticasone + salmeterol. Patients treated with inhaled fluticasone for chronic obstructive pulmonary disease (COPD) are more prone to pneumonia.慢性阻塞性肺疾病（COPD）：不要使用氟替卡松+沙美特罗。接受吸入性氟替卡松治疗慢性阻塞性肺疾病（COPD）的患者更容易患肺炎。
Prescrire Int. 2007 Dec;16(92):257-8.
10
Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.布地奈德/福莫特罗与沙美特罗/氟替卡松及沙丁胺醇相比，在慢性阻塞性肺疾病和可逆性气道阻塞患者中起效更快。
Respirology. 2007 Sep;12(5):732-9. doi: 10.1111/j.1440-1843.2007.01132.x.

引用本文的文献

1
Risk of Fracture and Osteoporosis in Patients With COPD and Inhaled Corticosteroids Treatment.COPD 患者和吸入皮质类固醇治疗患者的骨折和骨质疏松风险。
Respir Care. 2023 Nov 25;68(12):1719-1727. doi: 10.4187/respcare.10933.
2
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.吸入性糖皮质激素与慢性阻塞性肺疾病患者的肺炎风险
Cochrane Database Syst Rev. 2014 Mar 10;2014(3):CD010115. doi: 10.1002/14651858.CD010115.pub2.
3
Combined corticosteroid and long-acting beta₂-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease.
联合使用皮质类固醇和长效β₂受体激动剂的单一吸入器与安慰剂治疗慢性阻塞性肺疾病的比较
Cochrane Database Syst Rev. 2013 Nov 10;2013(11):CD003794. doi: 10.1002/14651858.CD003794.pub4.
4
Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease.吸入器中联合使用皮质类固醇和长效β受体激动剂与安慰剂治疗慢性阻塞性肺疾病的比较
Cochrane Database Syst Rev. 2007 Oct 17(4):CD003794. doi: 10.1002/14651858.CD003794.pub3.